Stanford BMT - CCT Oral presentations at ASH 2020:

129 Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma: Sham Mailankody, MBBS1, Jeffrey V. Matous, MD2, Michaela Liedtke, MD3, Surbhi Sidana, MD4, Shahbaz Malik, MD5*, Rajneesh Nath, MD6, Olalekan O. Oluwole, MBBS, MPH7, Erin E. Karski8*, Wade Lovelace8*, Xiangdong Zhou, PhD8*, Srinand Nandakumar, PhD8*, Arun Balakumaran, MD, PhD8 and Parameswaran Hari, MD, MRCP9

199 Profiling T-Cell Receptor Diversity and Dynamics during Lymphoma Immunotherapy Using Cell-Free DNA (cfDNA): Navika D Shukla1*, Alexander F. M. Craig, MPhil2, Brian Sworder, MD, PhD1, David M. Kurtz, MD, PhD1, Charles Macaulay, MSc, BA3*, Andrea Garofalo, BS, BA1*, Matthew J. Frank, MD, PhD4, Stefan Alig, MD1*, George Duran, BA5*, Youn H. Kim, MD6, James Zehnder, MD7, Crystal L. Mackall, MD8, David B. Miklos, MD, PhD4, Maximilian Diehn, MD, PhD9*, Michael S. Khodadoust, MD, PhD10 and Ash A. Alizadeh, MD, PhD11

310 - Disparities in the Use of Allogeneic Hematopoietic Stem Cell Transplant Among Children, Adolescents, and Young Adults with Acute Leukemia in California: Lena E. Winestone, MD, MSHP1,2, Qian Li, MS3*, Lori S. Muffly, MD, MS4, Kelly D Getz5*, Elysia Alvarez, MD, MPH3*, Ted Wun, MD3 and Theresa Keegan, PhD, MS3

353 - Belumosudil for Chronic Graft-Versus-Host Disease (cGVHD) after 2 or More Prior Lines of Therapy: The Rockstar Study (KD025-213): Corey Cutler, MD, MPH, FRCPC1, Stephanie J. Lee, MD, MPH2, Sally Arai, MD, MS3, Marcello Rotta, MD4, Behyar Zoghi, MD5*, Aravind Ramakrishnan, MD6, David Eiznhamer, PhD7*, Olivier Schueller, PhD8*, Zhongming Yang, PhD9*, Laurie S. Green, MEd10*, Sanjay K. Aggarwal, MD8*, Bruce R. Blazar, MD11, Steven Z. Pavletic, MD, MS12 and Madan Jagasia, MBBS, MS, MMHC13

354 Orca-T, a Precision Treg-Engineered Donor Product, Prevents Acute Gvhd with Less Immunosuppression in an Early Multicenter Experience with Myeloablative HLA-Matched Transplants: Everett H Meyer, MD, PhD1*, Rasmus Hoeg, MD2*, Anna Moroz, MD, PhD3*, Bryan Xei, BS4*, Hsin-Hsu Wu, MD5*, Rahul Pawar5*, Kartoosh Heydari, MD5*, David B. Miklos, MD, PhD1, Parveen Shiraz, MD1, Lori S. Muffly, MD, MS6, Sally Arai, MD, MS1, Laura J. Johnston, MD1, Robert Lowsky, MD, FRCP1, Andrew R. Rezvani, MD1, Judith A Shizuru, MD, PhD1, Wen-Kai Weng, MD, PhD7, Nathaniel Fernhoff, PhD8*, Gerhard Bauer9*, Arpita Gandhi, MD, MS10*, Amy Putnam8*, J. Scott Scott McClellan, MD, PhD11, Bronwen E. Shaw, PhD, MRCP, FRCPath12, Joseph P. McGuirk, DO13, Mehrdad Abedi, MD14 and Robert S. Negrin, MD1

556 - CD58 Aberrations Limit Durable Responses to CD19 CAR in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel but Can be Overcome through Novel CAR Engineering: Robbie G. Majzner, MD1, Matthew J. Frank, MD, PhD2, Christopher Mount, MD, PHD3*, Aidan Tousley3*, David M. Kurtz, MD, PhD4, Brian Sworder, MD, PhD5, Katherine A Murphy6*, Antigoni Manousopoulou7*, Kennedy Kohler3*, Maria Caterina Rotiroti, PhD3*, Jay Y. Spiegel, MD, FRCPC2, Yasodha Natkunam, MD, PhD8, Sheren F. Younes, MD, PhD9*, Elena Sotillo, PhD1*, Vandon Duong3*, Charles Macaulay, MSc, BA10*, Zinaida Good, PhD11, Peng Xu, MD3*, Louai Labanieh1*, Leo D Wang, MD, PhD12, Ash A. Alizadeh, MD, PhD4, Michelle Monje, MD, PHD3*, David B. Miklos, MD, PhD2 and Crystal L. Mackall, MD11

622 - Treatment Patterns, Type of Front-Line Regimen, and Outcomes Among Older Adults with Acute Myeloid Leukemia: A Population-Based Analysis in the Modern Era: Vanessa E Kennedy, MD1, Theresa Keegan, PhD, MS2, Qian Li, MS3*, Fran Maguire, PhD, MPH4* and Lori S. Muffly, MD, MS5

495 Survival Following Post-HCT Relapse in Adult Acute Lymphoblastic Leukemia Has Improved in the Era of Novel Immunotherapies: A Single Institution Analysis: Juliana Craig, BA1*, Maria Iglesias, BS1*, Kristen Cunanan, PhD2*, Sally Arai, MD, MS3, Matthew J. Frank, MD, PhD3, Laura J. Johnston, MD3, Robert Lowsky, MD, FRCP3, Everett H Meyer, MD, PhD3*, David B. Miklos, MD, PhD3, Robert S. Negrin, MD3, Andrew R. Rezvani, MD3, Judith A Shizuru, MD, PhD3, Surbhi Sidana, MD4, W-K Weng, MD, PhD5, Parveen Shiraz, MD3 and Lori S. Muffly, MD, MS6

736 - CD22-Directed CAR T-Cell Therapy Mediates Durable Complete Responses in Adults with Relapsed or Refractory Large B-Cell Lymphoma after Failure of CD19-Directed CAR T-Cell Therapy and High Response Rates in Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: John H. Baird, MD1,2, Matthew J. Frank, MD, PhD1,2, Juliana Craig, BA1*, Shabnum Patel, PhD3*, Jay Y. Spiegel, MD, FRCPC1,2, Bita Sahaf, PhD1*, Sheren F. Younes, MD, PhD4*, Jean S. Oak, MD, PhD5*, Yasodha Natkunam, MD, PhD5, Zachary Ehlinger, MS3*, Warren D. Reynolds, BS3*, Sally Arai, MD, MS2, Laura J. Johnston, MD2, Robert Lowsky, MD, FRCP2, Robert S. Negrin, MD6, Andrew R. Rezvani, MD2, Parveen Shiraz, MD2,3, Surbhi Sidana, MD3,6, Wen-Kai Weng, MD, PhD2, Liora M. Schultz, MD7, Sneha Ramakrishna, MD8, Kara L Davis, DO9, Steven A. Feldman, PhD3*, Crystal L. Mackall, MD1,10, David B. Miklos, MD, PhD2,11 and Lori S. Muffly, MD, MS1,12

Stanford BMT - CCT Poster Abstracts:

1034 Routine Use of Gemtuzumab Ozogamicin in 7+3-Based Inductions for All “Non-Adverse” Risk AML: Gavin Hui, MD1*, Abdullah Ladha, MD2*, Edna Cheung, PharmD3*, Caroline Berube, MD4, Steven Coutre, MD4, Jason Gotlib, MD, MS4, Michaela Liedtke, MD4, Tian Y Zhang, MD, PhD4, Lori S. Muffly, MD, MS2 and Gabriel N. Mannis, MD4

1507 Outcomes after Autologous Stem Cell Transplant in Patients with Relapsed Multiple Myeloma: Christopher Lemieux, MD1, Juliana Craig, BA1*, David Iberri, MD1, Sally Arai, MD, MS1, Laura J. Johnston, MD1, Robert Lowsky, MD, FRCP1, Lori S. Muffly, MD, MS1, Parveen Shiraz, MD1, Michaela Liedtke, MD2, Andrew R. Rezvani, MD1, Matthew J. Frank, MD, PhD1, Wen-Kai Weng, MD, PhD1, Everett H Meyer, MD, PhD1*, Judith A Shizuru, MD, PhD1, Robert S. Negrin, MD1, David B. Miklos, MD, PhD1 and Surbhi Sidana, MD1

1788 Bleeding and Thrombosis Are Associated with Endothelial Dysfunction in CAR-T Cell Therapy and Are Increased in Patients Experiencing Neurologic Toxicity: Andrew Johnsrud, MD1, Juliana Craig, BA1*, John H. Baird, MD1,2, Jay Y. Spiegel, MD, FRCPC1, Lori S. Muffly, MD, MS3, James Zehnder, MD4, Robert S. Negrin, MD1, Laura J. Johnston, MD1, Sally Arai, MD, MS1, Judith A Shizuru, MD, PhD1, Robert Lowsky, MD, FRCP1, Everett H Meyer, MD, PhD1*, Wen-Kai Weng, MD, PhD1, Parveen Shiraz, MD1, Andrew R. Rezvani, MD1, Theresa Latchford, RN1*, Crystal L. Mackall, MD5, David B. Miklos, MD, PhD1, Matthew J. Frank, MD, PhD1 and Surbhi Sidana, MD6

3255 - Molecular Imaging of Chimeric Antigen Receptor T Cells By ICOS-Immunopet: Federico Simonetta, MD, PhD1*, Israt S. Alam, PhD2*, Juliane K. Lohmeyer, MD1*, Bita Sahaf, PhD3*, Zinaida Good, PhD3, Weiyu Chen, PhD4*, Zunyu Xiao, MD, PhD4*, Toshihito Hirai, MD, PhD1,5*, Lukas Scheller, MD6*, Pujan Engels, M.Sc.6*, Ophir Vermesh, MD, PhD2*, Elise Robinson7*, Tom Haywood, PhD7*, Ataya Sathirachindra7*, Jeanette Baker1*, Meena B. Malipatlolla8*, Liora M. Schultz, MD9, Jay Y. Spiegel, MD, FRCPC10, Jason T. Lee, PhD11*, David B. Miklos, MD, PhD10, Crystal L. Mackall, MD3,12, Sanjiv S. Gambhir, MD, PhD2* and Robert S. Negrin, MD10

1144 Intratumoral CpG, Local Radiation, and Oral Ibrutinib Combine to Produce Effective in Situ Vaccination in Patients with Low-Grade B-Cell Lymphoma: Tanaya Shree, MD, PhD, BA1, Michael S. Khodadoust, MD, PhD2, Debra K. Czerwinski, BA1, Matthew J. Frank, MD, PhD3, Sara Beygi, MD4*, Steven R. Long, MD5*, Brock Martin, MD6* and Ronald Levy, MD

1457 First Report of Non-Genotoxic Conditioning with JSP191 (anti-CD117) and Hematopoietic Stem Cell Transplantation in a Newly Diagnosed Patient with Severe Combined Immune Deficiency: Rajni Agarwal, MD1, Kenneth I. Weinberg, MD2, Hye-Sook Kwon, PhD3*, Anne Le3*, Janel R Long-Boyle, PharmD, PhD4,5*, Donald B. Kohn, MD6, Kathryn Bradford, MD7*, Satiro De Oliveira, MD7*, Alice Bertaina, MD, PhD1, Agnieszka Czechowicz, MD, PhD1, Matt Porteus, MD, PhD1, David C Shyr, MD1*, Katja G Weinacht, MD, PhD1*, Ami J Shah, MD1, Melissa Mavers, MD, PhD1, Elisabeth Merkel, RN1*, Janice W Brown, MD3, Christopher C. Dvorak, MD4, Robertson Parkman, MD1, Maria Grazia Roncarolo, MD1 and Judith A Shizuru, MD, PhD1,8

3322 - Outcomes after Second Allogeneic Transplantation and Donor Lymphocyte Infusion for Relapse after a First Allogeneic Transplant: Christopher Lemieux, MD, Lori S. Muffly, MD, MS, Sally Arai, MD, MS, Andrew R. Rezvani, MD, Surbhi Sidana, MD, Laura J. Johnston, MD, Wen-Kai Weng, MD, PhD, Parveen Shiraz, MD, Matthew J. Frank, MD, PhD, Everett H Meyer, MD, PhD*, Judith A Shizuru, MD, PhD, David B. Miklos, MD, PhD, Robert S. Negrin, MD and Robert Lowsky, MD, FRCP

3332 Long-Term Outcomes of Patients with Peripheral T-Cell Lymphoma after Autologous Hematopoietic Cell Transplantation: Olivier Veilleux, MD1*, Francisco Socola, MD1, Sally Arai, MD, MS2, Robert Lowsky, MD, FRCP2, Judith A Shizuru, MD, PhD3, Parveen Shiraz, MD2, Lori S. Muffly, MD, MS4, Laura J. Johnston, MD4, Matthew J. Frank, MD, PhD2, Surbhi Sidana, MD1, Everett H Meyer, MD, PhD2*, Andrew R. Rezvani, MD2, David B. Miklos, MD, PhD2, Robert S. Negrin, MD4 and Wen-Kai Weng, MD, PhD2

975 Monitoring Measurable Residual Disease Using Peripheral Blood in Acute Lymphoblastic Leukemia: Results of a Prospective, Observational Study: Lori S. Muffly, MD, MS1, Vandana Sundaram, MPH2*, Connie Chen3*, Ilana Yurkiewicz, MD, BS4, Eric Kuo5*, Sarah Burnash3*, Jay Y. Spiegel, MD, FRCPC3, Kelly Chyan3*, Sally Arai, MD, MS3, Matthew J. Frank, MD, PhD3, Laura J. Johnston, MD3, Robert Lowsky, MD, FRCP3, Everett H Meyer, MD, PhD3*, Robert S. Negrin, MD3, Andrew R. Rezvani, MD3, Surbhi Sidana, MD6, Parveen Shiraz, MD3, Judith A Shizuru, MD, PhD7, Wen-Kai Weng, MD, PhD3, Michaela Liedtke, MD8, Hyma T. Vempaty, MD9 and David B. Miklos, MD, PhD3

1424 5-Azacytidine Depletes Hematopoietic Stem Cells and Synergizes with an Anti-CD117 Antibody to Augment Engraftment of Donor Stem Cells in Immunocompetent Mice: Andriyana K Bankova, MD1*, Wendy W Pang, MD, PhD1, Brenda J Velasco1*, Janel R Long-Boyle, PharmD, PhD2,3* and Judith A Shizuru, MD, PhD1,4,5,6

3169 - Response Evaluation Using PET/CT in Multiple Myeloma Patients Undergoing Autologous Transplant: Tim Ellis-Caleo, MD1*, Surbhi Sidana, MD2, Michaela Liedtke, MD3 and David Iberri, MD3

1526 Hypomethylating Agents in Combination with Venetoclax As a Bridge to Allogeneic Transplant in Acute Myeloid Leukemia: Vanessa E Kennedy, MD1, Gavin Hui, MD2*, Daria Gaut, MD3, Varun Mittal, MD4, Caspian Oliai, M.D.5, Lori S. Muffly, MD, MS6, Aaron C. Logan, MD, PhD, MPhil7 and Gabriel N. Mannis, MD8

2525 Intensity of Front-Line Regimen Is Associated with Admissions, in-Hospital Days, and Discharge Destination in Older Adults with Acute Myeloid Leukemia: A Population-Based Analysis: Vanessa E Kennedy, MD1, Theresa Keegan, PhD, MS2, Qian Li, MS3*, Fran Maguire, PhD, MPH4* and Lori S. Muffly, MD, MS5

Multi-site Poster Abstracts with Stanford BMT – CCT Investigators:

3335 Maintenance Use Is More Important Than the Choice of Bortezomib-Based Triplet Induction in Newly Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplantation: Surbhi Sidana, MD1, Shaji K. Kumar, MD2, Raphael Fraser, PhD3*, Noel Estrada-Merly, MS4*, Maxim Norkin, MD, PhD5*, Sergio Giralt, MD6*, Muzaffar H. Qazilbash, MD7, Nina Shah, MD8 and Anita D'Souza, MD, MS9

1187 Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel):  Caron Jacobson, MD, MMSc1, Frederick L. Locke, MD2, Armin Ghobadi, MD3, David B. Miklos, MD, PhD4, Lazaros J. Lekakis, MD5*, Olalekan O. Oluwole, MBBS, MPH6, Yi Lin, MD, PhD7, Ira Braunschweig, MD8*, Brian T. Hill, MD9, John M. Timmerman, MD10, Abhinav Deol, MD11, Patrick M. Reagan, MD12, Patrick J. Stiff, MD13, Ian W. Flinn, MD, PhD14, Umar Farooq, MD15, Andre H. Goy, MD16, Peter A. McSweeney, MD17*, Javier Munoz, MD18, Tanya Siddiqi, MD19, John M. Rossi, MS20*, Adrian Bot, MD, PhD20*, Lianqing Zheng, PhD20*, Remus Vezan, MD, PhD20, Zahid Bashir, MBBS20*, Jenny J. Kim, MD, MS20*, Rong Chu, PhD20* and Sattva S. Neelapu, MD21

1658 Clinical Experience of Tabelecleucel in Patients with EBV+ Primary (PID) or Acquired Immunodeficiency (AID) Associated Lymphoproliferative Disease: S Nikiforow, MD, PhD1, Robert Baiocchi, MD, PhD2, S Nasta, MD3, W-K Weng, MD, PhD4, D Loeb5*, K M Mahadeo, MD6, J Whangbo, MD, PhD1, P Phuong7*, W Navarro, MD7, L Gamelin7*, Y Sun, PhD8*, N Guzman-Becerra8* and S Prockop, MD9

2100 Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access and Commercial Out-of-Specification (OOS) Product: Caron A. Jacobson, MD1, Frederick L. Locke, MD2, David B. Miklos, MD, PhD3, Julie M. Vose, MD, MBA4, Yi Lin, MD, PhD5, Lihua E Budde, MD, PhD6, David G. Maloney, MD, PhD7, Samantha Jaglowski, MD, MPH8, Peter A. Riedell, MD9*, Lazaros J. Lekakis, MD10*, Miguel-Angel Perales, MD11, Jenny J. Kim, MD, MS12*, Jun Kawashima, MD12*, Yin Yang, MS12*, John M. Rossi, MS12*, Lovely Goyal, PhD12* and Sattva S. Neelapu, MD13

2329 RNA and TCR Sequencing Shed Light on Mechanisms of Treg Suppression in a Murine Model of Acute GvHD: Juliane K. Lohmeyer, MD1*, Toshihito Hirai, MD, PhD1,2*, Mustafa Turkoz, PhD1*, Natalie Koehler, PhD1,3*, Jeanette Baker1*, Stephane Buhler, PhD4*, Jean Villard, MD, PhD4*, Xuhuai Ji, MD, PhD5*, Federico Simonetta, MD, PhD1,6* and Robert S. Negrin, MD7

2554 - Clinical Experience of Tabelecleucel in Patients with Life-Threatening Complications of Epstein-Barr Virus Viremia: L Torno, MD1*, A Dahlberg, MD2*, Armin Ghobadi, MD3, P Stiff, MD4, R Reshef, MD5, W-K Weng, MD, PhD6, W Navarro, MD7, L Gamelin7*, R Dinavahi7*, Y Sun, PhD8*, N Guzman-Becerra8* and S Prockop, MD9

2103 ZUMA-19: A Phase 1/2 Multicenter Study of Lenzilumab Use With Axicabtagene Ciloleucel (Axi‑Cel) in Patients (Pts) With Relapsed or Refractory Large B Cell Lymphoma (R/R LBCL): Saad S. Kenderian, MD1, Olalekan O. Oluwole, MBBS, MPH2, Philip L. McCarthy, MD3, Ran Reshef, MD4, Parveen Shiraz, MD5, Omar Ahmed, PharmD6*, John Le Gall, MD, MBA7*, Myrna Nahas, MD7*, Lily Tang, PhD7* and Sattva S. Neelapu, MD8

1120 One-Year Follow-up of ZUMA-2, the Multicenter, Registrational Study of KTE-X19 in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Michael Wang, MD1, Javier Munoz, MD2, Andre H. Goy, MD3, Frederick L. Locke, MD4, Caron A. Jacobson, MD5*, Brian T. Hill, MD6, John M. Timmerman, MD7, Houston Holmes8*, Samantha Jaglowski, MD, MPH9, Ian W. Flinn, MD, PhD10, Peter A. McSweeney, MD11*, David B. Miklos, MD, PhD12, John M. Pagel, MD, PhD13, Marie José Kersten, MD, PhD14, Noel Milpied15*, Henry C.H. Fung, MD16*, Max S. Topp, MD17, Roch Houot, MD, PhD18*, Amer Beitinjaneh, MD, MPH, MSc19*, Weimin Peng, PhD20*, Lianqing Zheng, PhD20*, John M. Rossi, MS20*, Swaminathan Murugappan, MD, PhD20*, Ioana Kloos, MD20* and Patrick M. Reagan, MD21